204 related articles for article (PubMed ID: 35877255)
21. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
22. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
[TBL] [Abstract][Full Text] [Related]
23. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
[TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib for the treatment of primary myelofibrosis.
Swaim SJ
Am J Health Syst Pharm; 2014 Mar; 71(6):453-62. PubMed ID: 24589536
[TBL] [Abstract][Full Text] [Related]
25. Ruxolitinib: a new treatment option for myelofibrosis.
Ganetsky A
Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison CN; Talpaz M; Mead AJ
Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
[TBL] [Abstract][Full Text] [Related]
27. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Mesa RA; Gotlib J; Gupta V; Catalano JV; Deininger MW; Shields AL; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Hare T; Erickson-Viitanen S; Sun W; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Clin Oncol; 2013 Apr; 31(10):1285-92. PubMed ID: 23423753
[TBL] [Abstract][Full Text] [Related]
28. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
29. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
Thomas JW; Jamy O; Shah MV; Vachhani P; Go RS; Goyal G
Leuk Res; 2022 Jan; 112():106770. PubMed ID: 34920340
[TBL] [Abstract][Full Text] [Related]
30. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
[TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Yacoub A; Odenike O; Verstovsek S
Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
33. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Deisseroth A; Kaminskas E; Grillo J; Chen W; Saber H; Lu HL; Rothmann MD; Brar S; Wang J; Garnett C; Bullock J; Burke LB; Rahman A; Sridhara R; Farrell A; Pazdur R
Clin Cancer Res; 2012 Jun; 18(12):3212-7. PubMed ID: 22544377
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors.
Breccia M; Assanto GM; Laganà A; Scalzulli E; Martelli M
Curr Opin Oncol; 2022 Nov; 34(6):729-737. PubMed ID: 36017560
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
[TBL] [Abstract][Full Text] [Related]
36. Trends in overall mortality among US veterans with primary myelofibrosis.
Tashi T; Yu J; Pandya S; Dieyi C; Scherber R; Parasuraman S
BMC Cancer; 2023 Jan; 23(1):48. PubMed ID: 36641455
[TBL] [Abstract][Full Text] [Related]
37. Optimizing the management of patients with myelofibrosis.
Manea PJ
Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
[TBL] [Abstract][Full Text] [Related]
38. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
[TBL] [Abstract][Full Text] [Related]
39. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
